KDOQI clinical practice guideline for diabetes and CKD: 2012 update

American Journal of Kidney Diseases

Volumn 60, Issue 5, 2012, Pages 850-886

  Rocco, Michael V ^a   Berns, Jeffrey S ^a  

^a NONE

Author keywords

Albuminuria; chronic kidney disease; Clinical Practice Guideline; diabetes; dyslipidemia; evidence based recommendation; KDOQI

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GEMFIBROZIL; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAVASTATIN; REPAGLINIDE; ROSIGLITAZONE; SIMVASTATIN; TOLAZAMIDE; TOLBUTAMIDE; UNINDEXED DRUG;

ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DIABETES MELLITUS; DIALYSIS; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIFE EXPECTANCY; MEDLINE; PATIENT CARE; PRACTICE GUIDELINE; QUALITATIVE ANALYSIS; RISK ASSESSMENT; SYSTEMATIC REVIEW;

DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84867497463     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.07.005     Document Type: Article

References (118)

1. I.H. de Boer, T.C. Rue, Y.N. Hall, P.J. Heagerty, N.S. Weiss, J. Himmelfarb Temporal trends in the prevalence of diabetic kidney disease in the United States JAMA 305 24 Jun 22 2011 2532 2539
2. US Renal Data System USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Am J Kidney Dis 59(1) suppl 1 2012 e1 e420
3. G. Eknoyan, N.W. Levin Impact of the new K/DOQI guidelines Blood Purif 20 1 2002 103 108
4. National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease Am J Kidney Dis 49 2 Suppl 2 Feb 2007 S1 S180
5. M.V. Rocco, J.S. Berns KDOQI in the era of global guidelines Am J Kidney Dis 54 5 Nov 2009 781 787
6. G. Eknoyan, N. Lameire, R. Barsoum The burden of kidney disease: improving global outcomes Kidney Int 66 4 Oct 2004 1310 1314
7. Y. Slinin, A. Ishani, T. Rector Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and chronic kidney disease: A systematic review for a clinical practice guideline for the National Kidney Foundation Am J Kidney Dis 60 5 2012 747 769
8. K. Uhlig, A. Macleod, J. Craig Grading evidence and recommendations for clinical practice guidelines in nephrology A position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 70 12 Dec 2006 2058 2065
9. The DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 14 Sep 30 1993 977 986
10. The DCCT Research Group Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial Kidney Int 47 6 Jun 1995 1703 1720
11. P.H. Wang, J. Lau, T.C. Chalmers Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes Lancet 341 8856 May 22 1993 1306 1309
12. D.M. Nathan, B. Zinman, P.A. Cleary Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005) Arch Intern Med 169 14 Jul 27 2009 1307 1316
13. Y. Ohkubo, H. Kishikawa, E. Araki Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study Diabetes Res Clin Pract 28 2 May 1995 103 117
14. M. Shichiri, H. Kishikawa, Y. Ohkubo, N. Wake Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients Diabetes Care 23 Suppl 2 Apr 2000 B21 B29
15. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 9131 Sep 12 1998 837 853
16. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 9131 Sep 12 1998 854 865
17. S.R. Levin, J.W. Coburn, C. Abraira Effect of intensive glycemic control on microalbuminuria in type 2 diabetes Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators Diabetes Care 23 10 Oct 2000 1478 1485
18. P. Reichard, B.Y. Nilsson, U. Rosenqvist The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus N Engl J Med 329 5 Jul 29 1993 304 309
19. A. Patel, S. MacMahon, J. Chalmers Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 24 Jun 12 2008 2560 2572
20. F. Ismail-Beigi, T. Craven, M.A. Banerji Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 376 9739 Aug 7 2010 419 430
21. W. Duckworth, C. Abraira, T. Moritz Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2 Jan 8 2009 129 139
22. J.A. Breyer, R.P. Bain, J.K. Evans Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy The Collaborative Study Group Kidney Int 50 5 Nov 1996 1651 1658
23. R. Klein, B.E. Klein, S.E. Moss, K.J. Cruickshanks, P.C. Brazy The 10-year incidence of renal insufficiency in people with type 1 diabetes Diabetes Care 22 5 May 1999 743 751
24. H. Mulec, G. Blohme, B. Grande, S. Bjorck The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy Nephrol Dial Transplant 13 3 Mar 1998 651 655
25. G. Nyberg, G. Blohme, G. Norden Impact of metabolic control in progression of clinical diabetic nephropathy Diabetologia 30 2 Feb 1987 82 86
26. H.H. Parving, P. Rossing, E. Hommel, U.M. Smidt Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience Am J Kidney Dis 26 1 Jul 1995 99 107
27. I.H. de Boer, W. Sun, P.A. Cleary Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes N Engl J Med 365 25 Dec 22 2011 2366 2376
28. The DCCT Research Group TDR Hypoglycemia in the Diabetes Control and Complications Trial Diabetes 46 2 Feb 1997 271 286
29. H.C. Gerstein, M.E. Miller, R.P. Byington Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 24 Jun 12 2008 2545 2559
30. D.E. Bonds, M.E. Miller, R.M. Bergenstal The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study BMJ 340 2010 b4909
31. A.V. Schwartz, E. Vittinghoff, D.E. Sellmeyer Diabetes-related complications, glycemic control, and falls in older adults Diabetes Care 31 3 Mar 2008 391 396
32. S. Greenfield, J. Billimek, F. Pellegrini Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study Ann Intern Med 151 12 Dec 15 2009 854 860
33. S. Shurraw, B. Hemmelgarn, M. Lin Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study Arch Intern Med 171 21 Nov 28 2011 1920 1927
34. C. Drechsler, V. Krane, E. Ritz, W. Marz, C. Wanner Glycemic control and cardiovascular events in diabetic hemodialysis patients Circulation 120 24 Dec 15 2009 2421 2428
35. B.I. Freedman, L. Andries, Z.K. Shihabi Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients Clin J Am Soc Nephrol 6 7 Jul 2011 1635 1643
36. Y. Hayashino, S. Fukuhara, T. Akiba Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study Diabetologia 50 6 Jun 2007 1170 1177
37. K. Kalantar-Zadeh, J.D. Kopple, D.L. Regidor A1C and survival in maintenance hemodialysis patients Diabetes Care 30 5 May 2007 1049 1055
38. T. Oomichi, M. Emoto, T. Tabata Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study Diabetes Care 29 7 Jul 2006 1496 1500
39. S. Shurraw, S.R. Majumdar, R. Thadhani, N. Wiebe, M. Tonelli Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis Am J Kidney Dis 55 5 May 2010 875 884
40. M.E. Williams, E. Lacson Jr., W. Wang, J.M. Lazarus, R. Hakim Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses Clin J Am Soc Nephrol 5 9 Sep 2010 1595 1601
41. J.E. Gerich, C. Meyer, H.J. Woerle, M. Stumvoll Renal gluconeogenesis: its importance in human glucose homeostasis Diabetes Care 24 2 Feb 2001 382 391
42. C. Hasslacher, W. Wittmann [Severe hypoglycemia in diabetics with impaired renal function] Dtsch Med Wochenschr 128 6 Feb 7 2003 253 256
43. I. Muhlhauser, G. Toth, P.T. Sawicki, M. Berger Severe hypoglycemia in type I diabetic patients with impaired kidney function Diabetes Care 14 4 Apr 1991 344 346
44. K. Asplund, B.E. Wiholm, B. Lundman Severe hypoglycaemia during treatment with glipizide Diabet Med 8 8 Oct 1991 726 731
45. A. Jonsson, T. Rydberg, G. Sterner, A. Melander Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function Eur J Clin Pharmacol 53 6 Feb 1998 429 435
46. B. Rosenkranz, V. Profozic, Z. Metelko, V. Mrzljak, C. Lange, V. Malerczyk Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment Diabetologia 39 12 Dec 1996 1617 1624
47. T. Inoue, N. Shibahara, K. Miyagawa Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure Clin Nephrol 60 2 Aug 2003 90 95
48. T. Nagai, M. Imamura, K. Iizuka, M. Mori Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure Diabetes Res Clin Pract 59 3 Mar 2003 191 194
49. S. Schumacher, I. Abbasi, D. Weise Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment Eur J Clin Pharmacol 57 2 May 2001 147 152
50. C. Hasslacher Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function Diabetes Care 26 3 Mar 2003 886 891
51. N.C. Sambol, J. Chiang, E.T. Lin Kidney function and age are both predictors of pharmacokinetics of metformin J Clin Pharmacol 35 11 Nov 1995 1094 1102
52. A. Frid, G.N. Sterner, M. Londahl Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations Diabetes Care 33 6 Jun 2010 1291 1293
53. R. Rachmani, I. Slavachevski, Z. Levi, B. Zadok, Y. Kedar, M. Ravid Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications Eur J Intern Med 13 7 Oct 2002 428 433
54. S.R. Salpeter, E. Greyber, G.A. Pasternak, E.E. Salpeter Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus Cochrane Database Syst Rev 4 2010 CD002967
55. H.J. Nye, W.G. Herrington Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 118 4 2011 c380 c383
56. H.L. Pilmore Review: metformin: potential benefits and use in chronic kidney disease Nephrology (Carlton) 15 4 Jun 2010 412 418
57. British National Formulary www.bnf.org Accessed November 15th, 2011
58. K.J. Lipska, C.J. Bailey, S.E. Inzucchi Use of metformin in the setting of mild-to-moderate renal insufficiency Diabetes Care 34 6 Jun 2011 1431 1437
59. Japanese Society of Nephrology Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease 2012 (In Japanese) Tokyo Igakusya (Tokyo, Japan) 2012
60. A. Grey Skeletal consequences of thiazolidinedione therapy Osteoporos Int 19 2 Feb 2008 129 137
61. FDA Postmarket Drug Safety Information for Patients and Providers, FDA significantly restricts access to the diabetes drug Avandia http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm226956.htm September 23, 2010
62. R.W. Snyder, J.S. Berns Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease Semin Dial 17 5 Sep-Oct 2004 365 370
63. H. Linnebjerg, P.A. Kothare, S. Park Effect of renal impairment on the pharmacokinetics of exenatide Br J Clin Pharmacol 64 3 Sep 2007 317 327
64. O.E. Johansen, R. Whitfield Exenatide may aggravate moderate diabetic renal impairment: a case report Br J Clin Pharmacol 66 4 Oct 2008 568 569
65. W.J. Weise, M.S. Sivanandy, C.A. Block, R.J. Comi Exenatide-associated ischemic renal failure Diabetes Care 32 2 Feb 2009 e22 e23
66. L.V. Jacobsen, C. Hindsberger, R. Robson, M. Zdravkovic Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide Br J Clin Pharmacol 68 6 Dec 2009 898 905
67. L. Morgan, C.B. Marenah, W.J. Jeffcoate, A.G. Morgan Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure Diabet Med 13 6 Jun 1996 514 519
68. M.S. Joy, W.T. Cefalu, S.L. Hogan, P.H. Nachman Long-term glycemic control measurements in diabetic patients receiving hemodialysis Am J Kidney Dis 39 2 Feb 2002 297 307
69. M. Inaba, S. Okuno, Y. Kumeda Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection J Am Soc Nephrol 18 3 Mar 2007 896 903
70. J.P. Riveline, J. Teynie, S. Belmouaz Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system Nephrol Dial Transplant 24 9 Sep 2009 2866 2871
71. B.I. Freedman, Z.K. Shihabi, L. Andries Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease Am J Nephrol 31 5 2010 375 379
72. J.M. Ng, M. Cooke, S. Bhandari, S.L. Atkin, E.S. Kilpatrick The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease Diabetes Care 33 11 Nov 2010 2310 2313
73. C. Saloranta, L. Groop, K. Ylinen, K. Teramo, E.M. Tolppanen, L.G. Tallgren The usefulness of micro- and macrochromatographic determinations of glycohemoglobin in diabetic patients with nephropathy Clin Nephrol 25 4 Apr 1986 186 192
74. M. Chonchol, T. Cook, J. Kjekshus, T.R. Pedersen, J. Lindenfeld Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency Am J Kidney Dis 49 3 Mar 2007 373 382
75. H.M. Colhoun, D.J. Betteridge, P.N. Durrington Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) Am J Kidney Dis 54 5 Nov 2009 810 819
76. R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 9374 Jun 14 2003 2005 2016
77. M. Tonelli, A. Keech, J. Shepherd Effect of pravastatin in people with diabetes and chronic kidney disease J Am Soc Nephrol 16 12 Dec 2005 3748 3754
78. C. Baigent, M.J. Landray, C. Reith The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 9784 Jun 25 2011 2181 2192
79. A.G. Jardine, H. Holdaas, B. Fellstrom Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study Am J Transplant 4 6 Jun 2004 988 995
80. C. Wanner, V. Krane, W. Marz Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 3 Jul 21 2005 238 248
81. B.C. Fellstrom, A.G. Jardine, R.E. Schmieder Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 14 Apr 2 2009 1395 1407
82. H. Holdaas, I. Holme, R.E. Schmieder Rosuvastatin in diabetic hemodialysis patients J Am Soc Nephrol 22 7 Jul 2011 1335 1341
83. W. Marz, B. Genser, C. Drechsler Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis Clin J Am Soc Nephrol 6 6 Jun 2011 1316 1325
84. Adolescent type 1 Diabetes cardio-renal Interventional Trial Research Group Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT) BMC Pediatr 9 2009 79
85. J.C. Ansquer, C. Foucher, S. Rattier, M.R. Taskinen, G. Steiner Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis 45 3 Mar 2005 485 493
86. T.M. Davis, R. Ting, J.D. Best Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 54 2 Feb 2011 280 290
87. M. Tonelli, D. Collins, S. Robins, H. Bloomfield, G.C. Curhan Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency Kidney Int 66 3 Sep 2004 1123 1130
88. A. Keech, R.J. Simes, P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 9500 Nov 26 2005 1849 1861
89. J. Shepherd, J.P. Kastelein, V.A. Bittner Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease Mayo Clin Proc 83 8 Aug 2008 870 879
90. J. Armitage, L. Bowman, K. Wallendszus Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 9753 Nov 13 2010 1658 1669
91. E. Link, S. Parish, J. Armitage SLCO1B1 variants and statin-induced myopathy - a genomewide study N Engl J Med 359 8 Aug 21 2008 789 799
92. R. Bilous, N. Chaturvedi, A.K. Sjolie Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials Ann Intern Med 151 1 Jul 7 2009 11 20
93. The EUCLID Study Group Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria Lancet 349 9068 Jun 21 1997 1787 1792
94. M. Mauer, B. Zinman, R. Gardiner Renal and retinal effects of enalapril and losartan in type 1 diabetes N Engl J Med 361 1 Jul 2 2009 40 51
95. H. Haller, S. Ito, J.L. Izzo Jr. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes N Engl J Med 364 10 Mar 10 2011 907 917
96. A. Patel, S. MacMahon, J. Chalmers Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 9590 Sep 8 2007 829 840
97. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 355 9200 Jan 22 2000 253 259
98. P. Ruggenenti, A. Fassi, A.P. Ilieva Preventing microalbuminuria in type 2 diabetes N Engl J Med 351 19 Nov 4 2004 1941 1951
99. S. Andersen, J. Brochner-Mortensen, H.H. Parving Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria Diabetes Care 26 12 Dec 2003 3296 3302
100. E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohde The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy The Collaborative Study Group N Engl J Med 329 20 Nov 11 1993 1456 1462
101. B.M. Brenner, M.E. Cooper, D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 12 Sep 20 2001 861 869
102. E.J. Lewis, L.G. Hunsicker, W.R. Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 12 Sep 20 2001 851 860
103. ACE Inhibitors in Diabetic Nephropathy Trialist Group Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin- converting enzyme inhibitors? A meta-analysis of individual patient data Ann Intern Med 134 5 Mar 6 2001 370 379
104. P. Hovind, L. Tarnow, P. Rossing Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study BMJ 328 7448 May 8 2004 1105 1109
105. B.A. Perkins, L.H. Ficociello, K.H. Silva, D.M. Finkelstein, J.H. Warram, A.S. Krolewski Regression of microalbuminuria in type 1 diabetes N Engl J Med 348 23 Jun 5 2003 2285 2293
106. I.H. de Boer, T.C. Rue, P.A. Cleary Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort Arch Intern Med 171 5 Mar 14 2011 412 420
107. A.S. Levey, D. Cattran, A. Friedman Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration Am J Kidney Dis 54 2 Aug 2009 205 226
108. P.J. Watkins, V. Parsons, M. Bewick The prognosis and management of diabetic nephropathy Clin Nephrol 7 6 Jun 1977 243 249
109. P. Finne, A. Reunanen, S. Stenman, P.H. Groop, C. Gronhagen-Riska Incidence of end-stage renal disease in patients with type 1 diabetes JAMA 294 14 Oct 12 2005 1782 1787
110. R. Kunz, C. Friedrich, M. Wolbers, J.F. Mann Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease Ann Intern Med 148 1 Jan 1 2008 30 48
111. J.F. Mann, R.E. Schmieder, M. McQueen Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 9638 Aug 16 2008 547 553
112. W.O. Cooper, S. Hernandez-Diaz, P.G. Arbogast Major congenital malformations after first-trimester exposure to ACE inhibitors N Engl J Med 354 23 Jun 8 2006 2443 2451
113. D.K. Li, C. Yang, S. Andrade, V. Tavares, J.R. Ferber Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study BMJ 343 2011 d5931
114. M. Porta, J.W. Hainer, S.O. Jansson Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials Diabetologia 54 6 Jun 2011 1298 1303
115. H.H. Parving, F. Persson, J.B. Lewis, E.J. Lewis, N.K. Hollenberg Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 23 Jun 5 2008 2433 2446
116. M.L. Caramori, P. Fioretto, M. Mauer The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 49 9 Sep 2000 1399 1408
117. R.J. Desnick Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval Expert Opin Biol Ther 4 7 Jul 2004 1167 1176
118. J. Lin, R.J. Glynn, N. Rifai Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial Diabetes Care 31 12 Dec 2008 2338 2343